Business Daily from THE HINDU group of publications
Saturday, Apr 14, 2007
ePaper
Business Daily from THE HINDU group of publications Saturday, Apr 14, 2007 ePaper |
|
|
|
|
|
|
|
Corporate
-
Mergers & Acquisitions
Our Bureau
Terms of offer As per the agreement, RLL will be offered equity share warrants on preferential basis with an initial payment of 20 per cent to the extent of 14.9 per cent post expanded equity.
Hyderabad April 13 The board of directors of Jupiter Bioscience Ltd (JBL) has approved the strategic business alliance on peptide pharmaceuticals signed with Ranbaxy Laboratories Ltd (RLL). In its meeting on Thursday, the Board approved and ratified the term sheet signed between Ranbaxy and the company. As per the agreement, Ranbaxy will be offered equity share warrants on preferential basis with an initial payment of 20 per cent to the extent of 14.9 per cent post expanded equity. JBL, the Hyderabad-based peptide pharmaceutical company, is also firming up its QIP (Qualified Institutional Placement) offer of up to Rs 100 crore. It is also in the process of conversion of promoter warrants into equity shares.
EGM on May 14
The stake offer to RLL is subject to the approval of shareholders in an Extraordinary General Meeting, the company informed the BSE in a notice on Friday. The board has also decided that 17,50,000 equity shares of Rs 10 each with a premium of Rs 136 per share are allotted to the promoter of the company, Mr Venkat R. Kalavakolanu, as preferential allotment. It has decided to convene the EGM of the company on May 14, for the purpose of the above-mentioned business.
More Stories on : Mergers & Acquisitions | Pharmaceuticals | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|